Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases

Autor(es):Mostrar menos -

Aikawa, Nadia Emi ; Balbi, Verena Andrade ; Borba, Eduardo Ferreira ; Tonacio, Adriana Coracini ; Sallum, Adriana Maluf Elias ; Campos, Lucia Maria Arruda ; Kozu, Katia Tomie ; Vendramini, Margarete Borges ; Fontoura, Nicole ; Azevedo, Adriana de Souza ; Schwarcz, Waleska Dias ; Sartori, Ana Marli Christovam ; Antonangelo, Leila ; Silva, Clovis Artur ; Bonfa, Eloisa

• Tipo de documento: Artigo Científico
• Fonte: VACCINE: X; v. 10, p. 4-pg., 2022-04-01.

Resumo

Yellow fever vaccine (YFV) is a live attenuated vaccine usually contraindicated for juvenile autoimmune rheumatic disease (JARD) patients. During the recent epidemic in Sao Paulo-Brazil, YFV was indicated for patients under low immunosuppression. Thirty JARD patients with inactive diseases undergoing low immunosuppression and 30 healthy controls (HC) were vaccinated with a fractional dose 17DD YFV (similar to 5495 IU) and evaluated 30 days later. JARD patients and controls had comparable median age (12.4 vs. 12 years, p = 0.250). Disease parameters remained stable 30 days after 17DD YFV (p > 0.05) and only mild adverse events were reported in both groups (p > 0.05). JARD and HC had similar seroprotection [93% vs. 100%;p = 0.49], seroconversion rates [96% vs. 100%;p = 0.489], and GMT [1249 vs.1293; p = 0.821]. Both groups had similar white-blood-cells kinetics with transient decreases in lymphocytes at D5 and neutrophils at D10, followed by full recovery at D30 (P < 0.05). In conclusion, 17DD YFV was safe and immunogenic in JARD. This study may contribute to recommendations for patients living/travelling to endemic areas. (C) 2021 The Authors. Published by Elsevier Ltd. (AU)

• Processo FAPESP: 15/03756-4 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
• Beneficiário: Eloisa Silva Dutra de Oliveira Bonfá
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/16162-3 - Campanha de vacinação de 2018 para febre amarela e influenza: segurança e imunogenicidade em pacientes com doenças autoimunes reumatológicas
• Beneficiário: Eduardo Ferreira Borba Neto
• Modalidade de apoio: Auxílio à Pesquisa - Regular